These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2808743)

  • 1. 1992. Is there the will for there to be a way?
    Currie WJ
    J Clin Pharmacol; 1989 Sep; 29(9):770-4. PubMed ID: 2808743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European registration: today, tomorrow, and beyond.
    Currie WJ
    J Clin Pharmacol; 1990 May; 30(5):386-9. PubMed ID: 2347953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving horizon of drug registration--Europe and beyond.
    Currie WJ
    Eur J Clin Pharmacol; 1990; 39(5):453-6. PubMed ID: 2076736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulation of medicines post 1992.
    Currie WJ
    Eur J Clin Pharmacol; 1989; 37(5):433-5. PubMed ID: 2598981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical regulation in the European Community: barriers to single market integration.
    Orzack LH; Kaitin KI; Lasagna L
    J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biosimilars, the journey has begun].
    Martos-Rosa A; Martínez-de la Plata JE; Morales-Molina JA; Fayet-Pérez A; Acosta-Robles PJ
    Farm Hosp; 2015 Mar; 39(2):114-7. PubMed ID: 25817091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug safety in the European community.
    Sauer F
    Drug Saf; 1990; 5 Suppl 1():141-8. PubMed ID: 2182057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and bioequivalence requirements in the European community.
    Rauws AG
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():519-32. PubMed ID: 1820933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
    Enzmann H; Schneider C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Legal requirements for health protection from the European viewpoint--uniform regulations or reciprocal recognition of public health norms?].
    Schlüter P
    Zentralbl Hyg Umweltmed; 1996 Dec; 199(2-4):105-18. PubMed ID: 9409912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory affairs and biotechnology in Europe. II. The CPMP, "High Tech" and Multi-State procedures.
    Tryzelaar B
    Biotherapy; 1989; 1(3):179-96. PubMed ID: 2701848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Revision of the European pharmaceutical legislation].
    Sitbon G
    Ann Pharm Fr; 2004 May; 62(3):201-6. PubMed ID: 15243354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutual recognition in the European system: A blueprint for increasing access to medicines?
    Škrnjug I; Uzeirbegović S; Romčević ML; Tomić S; Meyer H; Conrad C
    Regul Toxicol Pharmacol; 2019 Aug; 106():270-277. PubMed ID: 31071381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
    Menges K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
    Bachmann P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Community requirements relating to drugs derived from human blood and plasma].
    Brunko P
    Ann Pharm Fr; 1994; 52(2):89-98. PubMed ID: 7944184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.